Defender experienced censorship on many social channels. Be sure to keep in touch with news that matters subscribe to our top news of the day. It’s free.
Ingon Pfizer making plans to keep it going billion dollar revenue down the stream go – by assuring investors annually the booster doses of COVID will be needed long before the end of the pandemic – a group of scientists from the Centers for Disease Control and Prevention (CDC) says there is not enough data to recommend the COVID booster shot in the general population.
the COVID-19 working group of the CDC’s Advisory Committee on Immunization Practices (ACIP) said on June 23, they only recommend booster shots if there is a demonstrated reduction in effectiveness –– not just a diminished antibody response.
Boosters may also be recommended if there is a different avoidance of vaccines, according to slide presented by Sara Oliver, MD, a medical epidemiologist with the CDC’s National Center for Immunization and Respiratory Diseases.
Today, there is no evidence to suggest a booster is needed, experts say. Boosters may be appropriate special risk groups in the future, including older people and transplant recipients. To be sure, chief public health officials have said they will continue to monitor the situation.
“I have to agree to interpret the working group in the sense that there is no data to support the recommendations to support the current proponents. Sharon Frey, ACIP member and clinical director of the Center for Vaccine Development at Saint Louis University Medical School. “There is no evidence against the current reduction in protection.”
Grace Lee, chair of the ACIP safety panel and professor of pediatrics at Stanford University School of Medicine, said she wanted to see more evidence of successful cases before recommending a booster shot.
“I want to be more confident in safety data when we’re talking about augmentation before it’s clear what the risk data looks like,” Lee said. “If we see severe trial cases then I think progress will be made even if there is no certainty in the safety data.”
CDC expert recommendations threaten Pfizer’s revenue
Shot shots for COVID are expected to serve as a key revenue driver in the coming years for Pfizer and Modern. Pfizer executives reassured investors the company sees the vaccine market changing as the pandemic disappears, and is likely to charge more per dose than getting pandemic supply deals.
Pfizer is working on two different booster strategies that it hopes could drive sales beyond immediate pandemic demand – a third 30 mg dose of current vaccines and an updated vaccine. referring to the South African race, Said the fierce Farma.
No one is entirely sure when a booster will be needed, but it’s possible that some of those vaccinated early may need an additional jab by September, or almost 8 to 12 months after their initial regime, the CEO Albert Bourla told Axios in May
Pfizer argued that advocates need “such as reducing blood antibody concentrations to ensure that the majority of the population does not carry the virus and quickly eradicates the epidemic,” Bernstein analysts, led by Ronny Gal, wrote to clients. That’s not the industry standard, nor is it what the CDIP recommends to its CDC meeting June 23, analysts wrote.
A Pfizer spokesperson told Fierce Pharma that “the company’s current thinking is that until we see a decrease in circulation of SARS-CoV-2 and COVID-19 disease, we think it is possible that the third dose, a expansion of our vaccine, may be necessary.to help provide protection against COVID-19, ”agreed to the regulatory approval.
The forecast is based on contracts to provide 1.6 billion doses of the vaccine this year. The company expects to sign several deals for this year and is in talks in several countries for 2022 and beyond.
During a investor conferences in March, Pfizer CFO Frank D’Amelio said the company saw “significant opportunity” for the COVID vaccine once the market moves from a “pandemic situation to an endemic situation.”
At that time “factors such as efficacy, ability to reproduce, clinical use were more important, and we saw that, in fact, an important opportunity for our vaccine from a point of view of need, from a price perspective, given the clinical profile of our vaccine, ”D’Amelio said the analyst.
During the The Barclays Global Health Conference in March, D’Amelio said the company did not take it as a one-time event, but “as something that will continue for the foreseeable future.”
Bourla said the company’s third dose of COVID vaccine is “likely” to be needed within a year from the initial two -dose inoculation – follow annual vaccination.
“Every year, you have to go to get your flu vaccine, ”Bourla said. “It’s similar to COVID. In a year, you go and get your annual shoot for COVID to protect. ”
Like Pfizer, Moderna’s chief commercial officer, Corinne M. Le Goff spoke while a call investors in April that Americans could start taking booster shots of its vaccine later this year to protect against COVID strains.
“It is likely that countries that have already achieved high vaccine coverage are ready to shift their focus to promoters by 2022, and may even start by the end of this year,” he said. Le Goff said.
5th time since the start of the COVID pandemic, the rise in Moderna’s stock price has made a billionaire while the vaccine is under increasing scrutiny for possible links to blood clotting and heart inflammation.
– Robert F. Kennedy Jr. (@RobertKennedyJr) June 17, 2021
Johnson & Johnson (J&J) states its vaccine may have to be given annually, even if it is sold by most consumers as a single dose vaccine.
As in The Defender reports in May, pharmaceutical companies and their CEOs earned billions from COVID vaccines, multiple fee packages and questionable stock sales while reassuring investors that plans go ahead boosters and annual shot.